.Matt Wilson et al N=1384 1L #DLBCL RCHOP/RCHOP-like pts Global collaboration Intercalated HDMTX vs End of treatment HDMTX No diff in CNS relapse rate or PFS/OS (landmark analysis) Intercalation results in RCHOP delays Fantastic effort Congrats to all involved #lymsm #ASH2021

#ASH21 abstracts are now live! Click here: loom.ly/U7wx2-w What abstracts are you most excited about? 🤩 Tells us via quote retweets or replies!

Nil new in the abstract for now, but do check out the live presentation from @anthonymatomd Updated data to include ~100 new #CLL pts (i.e. approx 270 total) treated with #pirtobrutinib and additional 10 months since the prior data cut presented. Don't miss it! #CLL #ASH21

🚨OPPORTUNITY ALERT! Our lab has a handful of fully-funded positions (starting 2022) for top-tier PhD students to develop cutting-edge ML for healthcare. If you're interested, get in touch; if you know someone who might be interested, please share this! 👇 vanderschaar-lab.com/join

What is next for #pirtobrutinib in #MCL ? Check out this trial in progress abstract BRUIN MCL321 Recruiting globally now! Loxo305 (pirtobrutinib) vs Investigator choice covalent BTKi in BTKi-naive R/R MCL. #ASH21

What is next for #pirtobrutinib in #CLL ? Check out this trial in progress abstract BRUIN CLL322 Recruiting globally now! Ven-R+Loxo305 (pirtobrutinib) vs Ven-R + placebo in covalent BTKi exposed or naive R/R CLL. #ASH21

Hermine et al Very long term (15y+) data for EMCLN trial RCHOP->ASCT vs RDHAP/RCHOP -> ASCT Nil Ritux Maintenance Long term benefit for HD Ara-C containing arm ? plateau on curve Are % of lower risk (low MIPI) pts functionally cured? #ASH21 #MCL #lymsm

CLL12 in @BloodJournal Langerbeins et al Ibrutinib vs observation in high risk asymptomatic TN Binet stage A #CLL Significant EFS benefit (HR 0.25) for #ibrutinib AE profile in placebo group is fascinating to see! No OS benefit (few events to date, long fup needed) #CLL #lymsm

We’re thrilled to announce the launch of Personalised Medicine from a Nordic Perspective on Coursera Instructor:@SisseOstrowski Carsten Niemann and Rudi Agius cover Personalised Medicine in CLL in Week 2! Join the free online course on Coursera: coursera.org/learn/personal…

For patients with CLL suffering from immunodeficiency, early antiviral therapy upon COVID-19 omicron BA.2 sublineage still seems warranted: medrxiv.org/content/10.110… #CLL #COVID19 PERSIMUNE @CLL_CLUE ERA-Net PerMed CLL lab Copenhagen

Thanks to all speakers who accepted to participate in the 12st Brazilian Lymphoma Conference!

We are hiring a Data Manager at CLL lab at Rigshospitalet, Copenhagen University. Please see the full call here: job.jobnet.dk/CV/FindWork/De…

MRD-guided therapy works in CLL - proud to publish together with @ArnonPkater and co-authors the primary analysis of the VISION/HO141 trial in Lancet Oncology: thelancet.com/journals/lanon…

Prediction of clinical outcome in CLL based on recurrent gene mutations, CLL-IPI variables, and (para)clinical data is now available online! sciencedirect.com/science/articl…

Next steps introducing decission support for patients with hematological malignancies CLL lab Copenhagen #CLL #PrecisionMedicine healthsciences.ku.dk/newsfaculty-ne…

Vær med til at forbedre behandlingen for vores patienter - forskningssekretær søges til vores aktive forskningsgruppe: regionh.dk/job/s%C3%B8g-j… Rigshospitalet CLL lab Copenhagen

Mulighed for at bringe personlig medicin et skridt videre - genopslag af data manager stilling i min forskningsgruppe: candidate.hr-manager.net/ApplicationIni… Rigshospitalet #data #datamanagement #forskning #BigData #MachineLearning